Scarica l'app Stockscreener
0.4972
2.09%
-0.0106
Dopo l'orario di chiusura:
.50
0.0028
+0.56%
Precedente Chiudi:
$0.5078
Aprire:
$0.51
Volume 24 ore:
1.81M
Relative Volume:
0.29
Capitalizzazione di mercato:
$31.88M
Reddito:
-
Utile/perdita netta:
$-51.50M
Rapporto P/E:
-0.1243
EPS:
-4
Flusso di cassa netto:
$-47.10M
1 W Prestazione:
-4.38%
1M Prestazione:
-72.68%
6M Prestazione:
-75.63%
1 anno Prestazione:
-73.55%
Intervallo 1D:
$0.481
$0.5184
Intervallo di 1 settimana:
$0.481
$0.541
Portata 52W:
$0.481
$3.39
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Nome
Outlook Therapeutics Inc
Settore
Industria
Telefono
(609) 619-3990
Indirizzo
111 S. WOOD AVENUE, ISELIN, NJ
Confronta OTLK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
0.4972 | 32.56M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-12-02 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-02-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-27 | Aggiornamento | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-08-30 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-07-13 | Iniziato | CapitalOne | Overweight |
| 2023-04-03 | Iniziato | Guggenheim | Buy |
| 2023-02-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Iniziato | BTIG Research | Buy |
| 2022-09-13 | Iniziato | Chardan Capital Markets | Buy |
| 2019-09-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2019-05-16 | Iniziato | Oppenheimer | Outperform |
| 2019-04-22 | Iniziato | Ascendiant Capital Markets | Buy |
Mostra tutto
Outlook Therapeutics Inc Borsa (OTLK) Ultime notizie
Can Outlook Therapeutics Inc. reach all time highs this yearJuly 2025 Review & Low Risk High Reward Trade Ideas - mfd.ru
Bull Run: Will Outlook Therapeutics Inc outperform the market in YEARWeekly Market Report & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Profit Recap: Can Manhattan Associates Inc expand into new markets2025 Earnings Impact & Long-Term Investment Growth Plans - baoquankhu1.vn
Insider Trends: Is Outlook Therapeutics Inc stock a falling knife or bargain buy2025 Volatility Report & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
US FDA declines to approve Outlook Therapeutics' eye disease drug - AOL.com
Will Outlook Therapeutics Inc. stock outperform international peersJuly 2025 Rallies & Free Real-Time Volume Trigger Notifications - ulpravda.ru
How Outlook Therapeutics Inc. (41ON) stock trades pre earnings2025 Price Momentum & Low Drawdown Trading Strategies - ulpravda.ru
How Outlook Therapeutics Inc. stock reacts to bond yieldsEarnings Performance Report & Accurate Entry and Exit Point Alerts - ulpravda.ru
Will Outlook Therapeutics Inc. (41O) stock beat revenue estimatesJuly 2025 Recap & Accurate Technical Buy Alerts - ulpravda.ru
Published on: 2026-01-09 04:38:07 - ulpravda.ru
What catalysts could drive Outlook Therapeutics Inc. stock higher2025 Performance Recap & Stepwise Trade Signal Implementation - ulpravda.ru
Published on: 2026-01-09 02:26:13 - ulpravda.ru
Is Outlook Therapeutics Inc. (41O) stock attractive for dividend growthMarket Risk Analysis & Fast Gain Swing Alerts - ulpravda.ru
Published on: 2026-01-08 22:18:30 - Улправда
Is Outlook Therapeutics Inc. stock oversold or undervaluedM&A Rumor & Accurate Entry/Exit Alerts - ulpravda.ru
Outlook Therapeutics Appoints Laura Cantrell as VP of Corporate Strategy and Business Development - VisionMonday.com
Is Outlook Therapeutics Inc. stock vulnerable to regulatory risksStock Rotation Strategies & High Return Portfolio Growth - ulpravda.ru
Outlook Therapeutics Inc. trading halted, news pending - MSN
OTLK Stock Crashes 67% in a Week: Here's What You Need to Know - sharewise.com
Outlook Therapeutics appoints Laura Cantrell as VP of corporate strategy By Investing.com - Investing.com Nigeria
Outlook Therapeutics appoints Laura Cantrell as VP of corporate strategy - Investing.com
Largest borrow rate increases among liquid names - TipRanks
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development - Quiver Quantitative
Outlook Therapeutics drops 80% on CRL for BLA for wet AMD asset - MSN
FDA rejects Outlook Therapeutics' third BLA submission of bevacizumab for wet AMD - Eyes On Eyecare
Outlook Therapeutics price target lowered to 50c from $1 at HC Wainwright - MSN
Outlook Therapeutics stock price target lowered to $0.50 at H.C. Wainwright - Investing.com Canada
Outlook Therapeutics stock price target lowered to $0.50 at H.C. Wainwright By Investing.com - Investing.com South Africa
Chardan Adjusts Price Target on Outlook Therapeutics to $1 From $3, Maintains Neutral Rating - marketscreener.com
OTLK: Chardan Capital Lowers Price Target, Maintains Neutral Rat - GuruFocus
What analysts say about Outlook Therapeutics Inc stockFlag and Pennant Patterns & Double Or Triple Wealth - earlytimes.in
Indegene Limited Included in Top Momentum ScanPortfolio Risk Assessment & Small Investment Big Gains - earlytimes.in
The Narrowing Pathway for Biotech Securities Fraud Claims: Lessons from Outlook Therapeutics - TipRanks
What to keep an eye on in 2026 - Eyes On Eyecare
A Second FDA Rejection Sparked A Rout In Outlook Therapeutics Shares - Stocktwits
Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK) and Lifecore Biomedical (LFCR) - The Globe and Mail
OTLK: HC Wainwright Maintains Neutral Rating, Lowers Price Targe - GuruFocus
Outlook Therapeutics price target lowered to $1 from $3 at Chardan - TipRanks
Outlook Therapeutics plunges 60% as FDA denies Lytenava approval | Tap to know more | Inshorts - Inshorts
Outlook Therapeutics price target lowered to 50c from $1 at H.C. Wainwright - TipRanks
Missed window? A third CRL sinks Outlook’s ONS-5010 - BioWorld MedTech
Outlook Left Adrift With Another FDA Rejection For Lytenava - Citeline News & Insights
Regulatory tracker: Outlook Therapeutics' ophthalmic bevacizumab hit with another FDA rejection - Fierce Pharma
Outlook Therapeutics shares plunge 61.4% after US FDA declines to approve eye disease drug - MarketScreener
What analysts say about Outlook Therapeutics Inc 41ON stockSector Leadership Analysis & Small Investment Big Gains - earlytimes.in
Outlook Therapeutics Inc Azioni (OTLK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):